⏳ Fetching live dividend data...
Home › Calculator › IPSEY Dividend Calculator 2026
Ipsen S.A. · OTC
Price: $46.75 · Annual div: $0.46/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in IPSEY → $168.8K in 10 years · $169.19/month
Ipsen S.A. operates as a global biopharmaceutical company, specializing in the research, development, and marketing of innovative medicines. Its therapeutic focus areas encompass oncology, neuroscience, gastroenterology, cognitive disorders, and various rare diseases. The company's diverse product portfolio includes significant oncology treatments like Somatuline, prescribed for neuroendocrine tumors and acromegaly; Decapeptyl, utilized for advanced metastatic prostate cancer; Cabometyx, targeting renal cell and second-line hepatocellular carcinoma; and Onivyde, for second-line metastatic pancreatic cancer. In neuroscience and endocrine care, Ipsen offers Dysport for motor muscular disorders and cosmetic applications, alongside NutropinAq and Increlex, both aimed at addressing growth failure in children and adolescents, with NutropinAq also indicated for adult growth hormone deficiency, Turner syndrome, and chronic renal failure. For gastrointestinal health, key products include Smecta for chronic and acute diarrhea as well as pain from functional bowel diseases; Forlax for constipation; and Fortrans/Eziclen for bowel preparation before medical procedures such as endoscopy, X-ray examinations, and colonic surgery. Tanakan is available for adults experiencing cognitive disorders, vestibular vertigo, vestibular rehabilitation, and tinnitus. Additional specialized offerings consist of Xermelo for carcinoid syndrome, Cometriq for medullary thyroid cancer, and Etiasa for inflammatory bowel diseases. Ipsen also provides consumer healthcare solutions like the Smebiocta/SmectaFlora Protect food supplement and SmectaGas, a medical device for the symptomatic treatment of gas-related digestive issues. Furthermore, its consumer healthcare segment features other gastrointestinal products such as Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. maintains strategic partnerships and agreements with numerous entities, including Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. The company was founded in 1929 and its corporate headquarters are located in Boulogne-Billancourt, France.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IPSEY position with:
Real after-tax yield depends on where you live and how you hold IPSEY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.99% | -1.81% | $99 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.84% | -1.96% | $84 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.79% | -2.01% | $79 / yr |
| 🇬🇧 UK ISA | 0% | 0.99% | -1.81% | $99 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.90% | -1.90% | $90 / yr |
| 🇨🇦 TFSA | 0% | 0.99% | -1.81% | $99 / yr |
| 🇨🇦 CA Taxable | 25% | 0.74% | -2.06% | $74 / yr |
| 🇦🇺 Super (pension) | 15% | 0.84% | -1.96% | $84 / yr |
| 🇦🇺 AU Taxable | 30% | 0.69% | -2.11% | $69 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.73% | -2.07% | $73 / yr |
| 🇫🇷 FR Taxable | 30% | 0.69% | -2.11% | $69 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.46/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
IPSEY pays quarterly — 4 times per year. Next ex-div: TBD.
How IPSEY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IPSEY sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IPSEY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →